ПРИМЕНЕНИЕ ПИТАВАСТАТИНА ПРИ САХАРНОМ ДИАБЕТЕ 2 ТИПА И ВЫСОКОМ СЕРДЕЧНО-СОСУДИСТОМ РИСКЕ: КЛИНИЧЕСКИЙ ПРИМЕР
Аннотация
В обзорной статье представлены данные о тактике лечения нарушения липидного обмена у больных сахарным диабетом (СД). Для наглядности представлен клинический пример пациента с СД и высоким сердечно-сосудистым риском, обусловленным в том числе выраженной гиперлипидемией. Анализируются результаты клинических исследований эффективности и безопасности питавастатина у больных с кардиометаболическими нарушениями. Отслеживается динамика показателей липидного спектра и гликемии на фоне курсовой терапии с применением питавастатина в суточной дозе 4 мг в сочетании с диетотерапией у больного СД.
Об авторах
М. А. Мамедов
ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России
Россия
Москва
Россия
Москва
М. А. Колчина
ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России
Россия
Москва
Россия
Москва
Список литературы
1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C,Wood DA, Zamorano JL; Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016, 37(39): 2999-3058. 2016 ESC/EAS guidelines for the management of dysli pidaemias.
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM, Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J, 2016, 37(29): 2315-2381.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ, 2003, 326(7404): 1419.
4. The Federal Service of State Statistics. Russian (Федеральная служба государственной статистики). www.gks.ru.
5. Распространенность факторов риска хронических неинфекционных заболеваний в российской популяции в 2012-2013 годах. Результаты исследования ЭССЭ-РФ. КВТиП, 2014, 13(6): 4-11).
6. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract, 2005, 59(2): 239-252.
7. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther, 2006, 80: 565-581.
8. Saito Y. Pitavastatin: An overview. Atheroscler Suppl, 2011 Nov, 12(3): 271-276.
9. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica, 2004, 34: 961-971.
10. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet, 2008, 47: 463-474.
11. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics, 2007, 8: 787-802.
12. Hounslow N. Pitavastatin has a low risk of drug-drug interactions: pharmacokinetic studies in combination with modulators of CYP450 and OATP. Presented at XVII International Symposium on Drugs Affecting Lipid Metabolism. Diabetes, Obesity, and the Metabolic Syndrome. Doha, Qatar, March 14-16, 2011.
13. Ramkumar S, Raghunath А Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin, 2016, 32: 631-639.
14. Pelliccia F, Rosano G, Marazzi G, Vitale C, Spoletini I, Franzoni F, Speziale G, Polacco M, Greco C, Gaudio C. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual anti platelet therapy. Circ J, 2014, 78(3): 679-684.
15. Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL)-The PATROL trial. Circ J, 2011, 75(6): 1493-1505.
16. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S. A 52-week, randomized, open-label, parallelgroup comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density li poprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density li poprotein cholesterol and glucose intolerance. Clin Ther, 2008, 30(6): 1089-1101.
17. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dysli pidemia. Clin Lipidol, 2009, 4(3): 291-302.
18. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis, 2010, 210(1): 202-208.
19. Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, Nishikawa T, Kodama T, Tada N, Saito Y. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis, 2008, 201(2): 345-352.
20. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther, 2010, 35(2): 139-151.
21. Fukutomi T, Takeda Y, Suzuki S, Ito T, Joh T, Itoh M. High density li poprotein cholesterol and apoli poprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor. Int J Cardiol, 2010, 141: 320-322.
22. Kakuda H, Kobayashi J, Nakato M, Takekoshi N. Shortterm effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men. Cholesterol, 2013, 2013: 314170.
23. Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, Nakamura Y, Iwakura A, Hara K, Yamamoto T, Kuroe A, Ohya M, Fujimoto S, Hamamoto Y, Honjo S, Ikeda H, Nabe K, Tsuda K, Inagaki N, Seino Y, Kume N, Kansai Investigation of Statin for Hyperli pidemic Intervention in Metabolism and Endocrinology Investigators. Effects of pitavastatin on li pid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperli pidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb, 2008, 15(6): 345-350.
24. Miller PE, Martin SS, Joshi PH, Jones SR, Massaro JM, D’gostino RB, Sponseller CA, Toth PP. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Li poprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperli pidemia or Mixed Dysli pidemia. Clin Ther, 2016, 38(3): 603-609.
25. Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, Hounslow N, Kastelein JJ, PASCAL Study Group. Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. J Pediatr, 2015 Aug, 167(2): 338-343.
26. Harada-Shiba M, Arisaka O, Ohtake A, Okada T, Suganami H, NK-104-PH 01 study registration group. Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia. J Atheroscler Thromb, 2016, 23(1): 48-55.
27. Saito Y. Critical appraisal of the role of pitavastatin in treating dysli pidemias and achieving li pid goals. Vasc Health Risk Manag, 2009, 5: 921-936.
28. Kodama K, Komatsu S, Ueda Y, Takayama T, Yajima J, Nanto S, Matsuoka H, Saito S, Hirayama A. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound – the TOGETHAR trial. Circ J, 2010, 74(9): 1922-1928.
29. Feng T, Huang X, Liang Q, Liang Y, Yuan Y, Feng L, Wu W, Xiao X, Han Y. Effects of Pitavastatin on Lipid-rich Carotid Plaques Studied Using High-resolution Magnetic Resonance Imaging. Clin Ther, 2017 Mar, 39(3): 620-629.
30. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol, 2012, 73: 518-535.
31. Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther, 2011 Sep, 28(9): 811-823.
Рецензия
Для цитирования:
Мамедов М.А., Колчина М.А. ПРИМЕНЕНИЕ ПИТАВАСТАТИНА ПРИ САХАРНОМ ДИАБЕТЕ 2 ТИПА И ВЫСОКОМ СЕРДЕЧНО-СОСУДИСТОМ РИСКЕ: КЛИНИЧЕСКИЙ ПРИМЕР. Атеротромбоз. 2018;(1):132-139. https://doi.org/10.21518/2307-1109-2018-1-132-139
For citation:
Mamedov M.N., Kolchina М.A. EVALUATING THE USE OF PITAVASTATIN IN TYPE 2 DIABETES MELLITUS AND HIGH CARDIOVASCULAR RISK: CLINICAL CASE. Aterotromboz = Atherothrombosis. 2018;(1):132-139. (In Russ.) https://doi.org/10.21518/2307-1109-2018-1-132-139
Просмотров: 726
Контент доступен под лицензией Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Послать статью по эл. почте 